Pfizer downgrades disitamab again
Padcev has eaten into bladder expectations, while a Tukysa trial has also gone.
Datroway and Trodelvy's new breast cancer battle
But the Astra/Daiichi ADC stumbles in lung cancer.
Like MacroGenics, Sanofi tries to square an uneasy circle
SGN-CEACAM5C carries the same antibody as the discontinued tusamitamab ravtansine.
Not so fast for AbbVie in SEZ6
A phase 3 trial is downgraded, and the second line now looks like the main focus for turmetabart adizutecan.
China’s latest Car-T bets revealed
First-in-human listings bring a bispecific and yet another in vivo Car-T.
Regeneron bets big on Lynozyfic
The company is starting four new pivotal trials this year.
